Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Project CARE: An Integrated Treatment Adherence Program for Bipolar Disorder at the Time of Prison Release - Open Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03825640
Recruitment Status : Recruiting
First Posted : January 31, 2019
Last Update Posted : February 1, 2019
Sponsor:
Collaborator:
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
Brown University

Brief Summary:

The aim of this program of research is to develop and pilot the CARE (Community treatment Adherence at Re-Entry) program, an adjunctive intervention for incarcerated individuals with bipolar disorder (BD) transitioning from prison to the community.

The purpose of this proposed project is to establish the feasibility, acceptability, and preliminary effects of this newly developed intervention on symptom outcomes.


Condition or disease Intervention/treatment Phase
Bipolar Disorder Behavioral: CARE Not Applicable

Detailed Description:

Bipolar disorder (BD) is a serious, disabling, and highly recurrent illness that is disproportionately represented in the criminal justice system. BD increases risk for several adverse outcomes for prisoners, including mood instability, suicide attempts, substance use relapse, and high rates of repeat incarceration. Despite these serious negative consequences, up to 70% of prisoners with BD do not receive mental health treatment upon prison release. Lack of engagement in ongoing mental health treatment for BD upon community re-entry represents one potent factor that perpetuates risk for adverse outcomes, and consequences of untreated BD (e.g., impulsivity, substance use) may greatly exacerbate difficulties in establishing stable living conditions (e.g., adequate housing, legal employment) at community re-entry. Thus, there is a critical need for interventions to facilitate engagement with treatment for BD during this vulnerable transition.

To that end, the primary aim of this study is to develop and establish the feasibility and acceptability of the Community treatment Adherence at Re-Entry (CARE) program. CARE is an innovative intervention that will combine evidence-based cognitive-behavioral, family, and telephone outreach strategies to promote treatment engagement and improve clinical outcomes for prisoners with BD during the period of community re-entry. CARE will include 3 individual and 1 family session, followed by 11 brief telephone contacts for up to 6 months post-release. Given its moderate intensity, adjunctive nature, use of community mental health counselors, and use of telephone administration for post-release follow-up, CARE has been designed with an eye toward community implementation. Its proposed mechanisms of action (i.e., increasing values-action consistency, enhancing social supports, and linkage to community treatment services) are further well matched to the practical and clinical needs of re-entering individuals.

The aim of this research is to conduct a small open trial (n=12) of the CARE intervention. Assessments will occur at baseline, immediately pre-release, 4 weeks post-release, and 24 weeks post-release (post-treatment). This study will examine the feasibility and acceptability of CARE (e.g., uptake, adherence to, and completion of the CARE intervention, satisfaction with the intervention, understanding of intervention principles) and of this research design. This study will also examine treatment effects (within relevant confidence intervals) on outcomes (e.g., mood symptoms). Change in potential mechanisms (i.e., values-action consistency derived from intervention principles) will be examined.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Project CARE (Community Treatment Adherence at Re-Entry): An Integrated Treatment Adherence Program for Bipolar Disorder at the Time of Prison Release - Open Trial
Actual Study Start Date : January 14, 2019
Estimated Primary Completion Date : January 2020
Estimated Study Completion Date : August 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bipolar Disorder

Arm Intervention/treatment
Experimental: Community treatment Adherence at Re-Entry (CARE)

CARE will begin within the 2 months before prison release, and will continue for 6 months after re-entry. CARE will be comprised of: a) 3 individual sessions with the CARE counselor; b) 1 optional family/significant other (SO) session; and c) 11 brief (15-20 min) follow-up telephone contacts with prisoners and their SO over the first 6 months post-release.

The CARE intervention will incorporate motivational strategies from existing interventions (e.g., Acceptance and Commitment Therapy) in order to clarify values and goals to enhance motivation for community treatment engagement and behavior change. CARE will also integrate bipolar disorder psychoeducation and strategies from existing family models of intervention for BD (e.g., McMaster Model of Family Functioning) that are designed to improve family communication, social support, and problem-solving around BD illness management over this vulnerable transition period.

Behavioral: CARE
Hybrid in-person and telephone-based adjunctive intervention for bipolar disorder across the transition from prison to the community.




Primary Outcome Measures :
  1. Client Satisfaction Questionnaire-8 (CSQ-8) [ Time Frame: 24 weeks post-release ]
    Intervention feasibility and acceptability; Total satisfaction scores range from 8 (low) to 32 (high)


Secondary Outcome Measures :
  1. Quick Inventory of Depressive Symptomatology - Self-Report (QIDS-SR) [ Time Frame: 24 weeks post-release ]
    depressive symptom severity; Total depressive symptom severity scores range from 0 (none) to 27 (very severe)

  2. Altman Self-Rating Scale for Mania (ASRM) [ Time Frame: 24 weeks post-release ]
    manic symptom severity; Total manic symptom severity scores range from 0 (none) to 20 (severe)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • DSM-5 diagnosis of bipolar I, bipolar II, or bipolar disorder not elsewhere classified
  • Anticipated prison release within 4-10 weeks
  • Expected release to locations anywhere within RI or to locations in other states within a 30 mile radius of Providence
  • Aged 18 or older
  • Willingness to sign an informed consent document that describes study procedures

Exclusion Criteria:

  • Presence of current psychiatric symptoms severe enough to warrant separation from the general prison population
  • Cognitive impairment sufficient to prevent successful completion of the baseline interview.
  • Inability to understand sufficiently well to understand the consent form or assessment instruments when they are read aloud.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03825640


Contacts
Layout table for location contacts
Contact: Lauren Weinstock, PhD 401-455-6304 Lauren_Weinstock@brown.edu
Contact: Hannah Graves, ScM 401-444-1953 Hannah_Graves@brown.edu

Locations
Layout table for location information
United States, Rhode Island
Rhode Island Department of Corrections Recruiting
Cranston, Rhode Island, United States, 02920
Contact: Jeff Renzi         
Brown University Recruiting
Providence, Rhode Island, United States, 02912
Contact: Lauren Weinstock, PhD    401-455-6304    Lauren_Weinstock@brown.edu   
Contact: Hannah Graves, ScM    401-444-1953    Hannah_Graves@brown.edu   
Sponsors and Collaborators
Brown University
National Institute of Mental Health (NIMH)
Investigators
Layout table for investigator information
Principal Investigator: Lauren Weinstock, PhD Brown University

Layout table for additonal information
Responsible Party: Brown University
ClinicalTrials.gov Identifier: NCT03825640    
Other Study ID Numbers: 1806002090
R34MH117198 ( U.S. NIH Grant/Contract )
First Posted: January 31, 2019    Key Record Dates
Last Update Posted: February 1, 2019
Last Verified: January 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Bipolar Disorder
Bipolar and Related Disorders
Mental Disorders